News|Articles|June 30, 2026

Roche Gets Priority Review for Enspryng; Announces Sequencing Platform

Listen

0:00 / 0:00

Key Takeaways

Priority review follows phase 3 placebo-controlled evidence across SatraGO-1/2, presented at ASOPRS 2025, demonstrating improvements in proptosis, inflammation, diplopia, and patient-reported outcomes.
IL‑6R blockade may address upstream autoimmune-inflammatory drivers of TED, and recycling antibody engineering is designed to prolong target engagement and enable convenient subcutaneous dosing.
Established global approvals in NMOSD and orphan-drug status provide a mature safety database and manufacturing experience, potentially derisking commercialization if TED authorization is granted.
AXELIOS 1 couples sequencing-by-expansion “Xpandomers” with reusable CMOS nanopore sensing, aiming for high-throughput single-molecule reads, near–real-time analysis, and same-day whole-genome turnaround.

The company’s thyroid eye disease treatment will be the first at-home subcutaneous disease-modifying treatment if approved.

Roche announced on June 30, 2026 that FDA granted priority review to the company’s supplemental biologics license application (sBLA) for satralizumab (Enspryng) for the treatment of thyroid eye disease (TED).¹The agency accepted the filing after 2 randomized, placebo-controlled global phase 3 SatraGO studies found consistent improvements of TED symptoms and a more favorable safety profile when compared with currently available treatments. The study data were presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery in October 2025.²

“The FDA’s decision to grant priority review to Enspryng is an important step toward expanding treatment options for people living with thyroid eye disease,” said Levi Garraway, MD, PhD, Roche’s chief medical officer and head of Global Product Development, in a press release.¹ “By targeting the underlying disease biology with a novel mechanism of action, this subcutaneous therapy has the potential to introduce a new treatment approach that combines clinical efficacy and a favorable safety profile with the convenience of at-home administration.”

TED is progressive, rare inflammatory autoimmune disease that can threaten sight. Symptoms include redness, swelling, eyelid retraction, eye bulging, double vision, and pain. TED impacts approximately 155 out of every 100,000 people and commonly occurs in people with hyperthyroidism.

What Makes Satralizumab Work?

Satralizumab is a humanized monoclonal antibody that targets IL-6, which is a messenger in the body’s inflammatory response, receptor activity, according to Roche. It was created using novel recycling antibody technology that allows for sustained IL-6 inhibition by binding to the IL-6 receptor.

Satralizumab is currently approved for the treatment of neuromyelitis optica spectrum disorder in 90 countries, including the United States and the European Union, where it has orphan drug designation. Roche is developing the treatment for additional neurological autoimmune and inflammatory diseases, including autoimmune encephalitis and myelin oligodendrocyte glycoprotein antibody-associated disease.

Roche Launches AXELIOS 1 Sequencing Platform

In other company news, on June 29, 2026, Roche launched its next-generation single-molecule sequencing platform, AXELIOS 1, powered by sequencing by expansion (SBX) technology. “The platform converts DNA/RNA into high signal‑to‑noise 'Xpandomers,' which are measured by a sequencing instrument using a reusable complementary metal–oxide–semiconductor sensor containing millions of nanopores. This architecture enables accurate, ultra‑rapid, flexible and high‑throughput, single‑molecule sequencing with near real‑time analysis,” the company stated in a press release.³

“AXELIOS 1 will deliver a disruptive sequencing solution that combines high accuracy with unprecedented speed and scalability. These attributes, combined with our high level of cost efficiency, will enable the sequencing community to develop applications that previously were not feasible,” said Matt Sause, CEO of Roche Diagnostics, in a press release.³ “Additionally, in the future, AXELIOS 1 has the same potential to enable the next generation of clinical applications and unlock new frontiers in personalized healthcare.”

The new platform can be used for smaller, faster batches or larger projects and can produce whole-genome results in the same day. The flexible open setup gives researchers freedom to explore and create new workflows to gain knowledge of complex diseases.

Library prep kits and free open-source bioinformatics analysis suite will be offered by Roche. The platform can also be built for use of other life sciences tools.

References

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED). Press release. Roche. June 30, 2026. https://www.roche.com/media/releases/med-cor-2026-06-30
Briceño C, et al. Primary Results of the Phase 3 SatraGO-1 and SatraGO-2 Trials: Efficacy and Safety of Satralizumab in Thyroid Eye Disease. Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Fall Scientific Symposium, October 16–17, 2025.
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform. Press release. Roche. June 29, 2026. https://www.roche.com/media/releases/med-cor-2026-06-29

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.